Skip to main content

Table 3 Important combinational studies for Ph ALL

From: Recent updates for antibody therapy for acute lymphoblastic leukemia

Type Frontline Ph ALL R/R Ph ALL
Ref [64] [65] [66] [67] [68]
Rigemen Sequential hyper-CVAD + BLN Mini-HCVD + IO ± BLN SWOG 1318: BLN + POMP SWOG 1312: CVP + IO Mini-HCVD + IO ± BLN
Capicity 27 64 31 48 84
Conditions 44% Salvage 1 38% Prior BLN 19% Prior HSCT 13% Primary refractory
40% CR1 duration  < 1 year
23% Prior HSCT
Median age [range] 38 [18–59] 68 [60–81] 73 [66–84] 43 [20–79] 35 [9–87]
Response (CR/CRi) 100% 98% 66% 61% 80%
MRD negativity by flow cytometry 96% 95% 92% 80%
Duration RFS 76% at 1 year 76% at 3 years DFS 56% at 1 year 52% at 2 years
OS rate 89% at 1 year 54% at 1 years 65% at 1 year Median 10.9 months 39% at 2 years
  1. Ph Philadelphia-chromosome, ALL acute lymphoblastic leukemia, CR complete remission, CRi complete remission with incomplete hematologic recovery, MRD measurable residual disease, OS overall survival, RFS relapse-free survival, mini-HCVD mini-hyper-fractionated cyclophosphamide, vincristine, dexamethasone, IO inotuzumab ozogamicin, HSCT hematopoietic stem cell transplant, hyper-CVAD, hyper-fractionated cyclophosphamide, vincristine, adriamycin, dexamethasone, CVP cyclophosphamide, vincristine, prednisone, SWOG South West Oncology Group, POMP prednisone, vincristine, methotrexate, mercaptopurine